Devatis, Inc. has been established in United States. As the parent company, DEVA Holding A.S., a long established multinational company headquartered in Istanbul, Turkey which is active since 1958 in pharmaceutical sector owns 100% of Devatis, Inc. shares. In addition to its activities in Turkey and various European and significant eastern territories, DEVA Holding A.S. has stepped into the territory of the USA by incorporating Devatis Inc.
In order to expand its services to human health in the US, Philipp D. Haas, having broad experience in pharmaceuticals business in various markets, is actively contributing to improve Devatis, Inc. and is acting as the President of Devatis Inc. which develops, markets and distributes quality branded pharmaceutical products directly.
Devatis, Inc. adheres to strict cGMP standards and has an excellent audit history with the US Food and Drug Administration (FDA). With over 60 years of combined pharmaceutical experience in public and private sectors in more than 60 countries, the leadership team is responsible for implementing business strategy assuring long-term success. Strategic partnerships are a vital component of current and future growth.
Established in 1958, DEVA Holding is among the well-established pharmaceutical manufacturers in Türkiye. With the main area of operations including manufacturing and marketing medicinal products for human and use and raw materials, DEVA Holding also manufactures veterinary medicines, eau de Cologne, and medical ampoules.
The majority of shares in DEVA Holding was acquired in 2006 by funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to assume management.
Currently, its product portfolio contains more than 650 products in 14 therapeutic areas, ranging from oncology to cardiology, respiratory system and ophthalmology, as well as medical devices.
With progressively expanding regional growth and export operations, DEVA Holding is the holder of 1,119 marketing authorizations in 65 countries, including the USA, Switzerland and Germany. Founded under the brand name of Devatis in Germany and then in Switzerland, the company received registration approval in 2018 and having been established in the USA under the same name, accelerated its activities. DEVA’s affiliates are Devatis Inc (US), Devatis Ltd (New Zealand), Devatis GmbH (Germany), Devatis AG (Switzerland), Devatis de Mexico S.DE RL. DE C.V (Mexico), Devatis Inc (Canada) and Devatis Pty Ltd (Australia).
DEVA Holding focuses on research and development to improve access to medicines for patients who need them, and all of its manufacturing facilities are certified compliant with the European GMP (Good Manufacturing Practice) and US FDA (Food and Drug Administration). DEVA Holding currently exports pharmaceuticals and pharmaceutical raw materials to more than 60 countries.
DEVA Holding develops high-quality and innovative products with its award-winning R&D center, DEVARGE, strong staff of well-trained employees who are experts in their respective fields, and full-fledged laboratories and manufacturing sites equipped with cutting-edge technology. DEVA invested 7% of its turnover to R&D activities in 2023.
With its manufacturing capabilities, DEVA Holding has become the domestic corporation with the most comprehensive production capabilities in Türkiye. Undertaking manufacturing operations at facilities in Çerkezköy and Kartepe, DEVA Holding holds an annual output capacity of 620 million units of medicines. While producing for public health, DEVA Holding also adopts the understanding of sustainability for the effective and efficient use of resources, and considers environmental sensitivities in its activities. DEVA Holding manages human rights, occupational health and safety, energy efficiency and waste with great care, and continues its activities with the awareness of leaving a more livable world to future generations with its employees who possesses environmental awareness and sustainability approach.
Continuing to work for a healthy and sustainable future, DEVA Holding also supports social responsibility projects, especially in the fields of education, public health and the environment.
DEVA Holding has approximately 650 products in 14 therapeutic areas including oncology, ophthalmology and respiratory system products among others. DEVA Holding has been creating difference by releasing new products into market each year consistently.
DEVA's manufacturing capacity allows production of different pharmaceutical forms at large scales:
The high quality of DEVA's production facilities are endorsed by globally recognized certification bodies:
DEVA has manufacturing facilities at two locations: Cerkezkoy and Kartepe. All the facilities are endorsed by internationally recognized certifications proving the high quality standards of DEVA.
Creams, Gels, Ointments, Suppository
Tablets, Capsules
Solutions, Suspensions, Syrups, Solutions and Suspensions for Nebulisers
